Forfatterskabserklæring • Ugeskrift for Læger

Det er derfor vigtigt, at alle forfatteroplysninger skrives direkte ind i formularen, de disse er obligatoriske, hvorefter den kan printes og underskrives. For artikler til Danish Medical Journal skal Authorship Declaration for DMJ udfyldes.

Manuskriptets titel:

En kvantitativ analyse af sammenhængen mellem størrelsen af caput femoris og skostørrelse

en hjælp til den travle ortopædkirurg.

UFL-nr. - (hvis kendt):

Artikeltype.:

Julenummer

Hermed erklæres og indestås for,

- at det i manuskriptet præsenterede arbejde ikke, hverken helt eller delvist, er publiceret andetsteds, og at det ikke for tiden vurderes i anden tidsskriftsredaktion,
- at der ikke foreligger ophavsretlige problemer i forbindelse med publikation af manuskriptet og at der er indhentet nødvendige copyrighttilladelser og patientsamtykker til illustrationer, figurer og fotos inkl. evt. personer på billedet,
- at nødvendige tilladelser og patientsamtykker til benyttelse af patientoplysninger, laboratoriedata, billedediagnostiske og patologiske undersøgelser osv. foreligger,
- at manuskriptet, såfremt det udgår fra en institution eller afdeling, er accepteret til fremsendelse i den foreliggende form af den ansvarlige på institutionen eller afdelingen,
- at, såfremt flere institutioner eller afdelinger har været involveret i et omtalt patientforløb, er alle relevante parter orienteret inden indsendelse af manuskriptet,
- at personer og institutioner, der er nævnt i taksigelsesafsnittet, har accepteret dette,

- at det i manuskriptet præsenterede arbejde, indtil det publiceres på www.ugeskriftet.dk eller i Ugeskrift for Læger, eller afvises, ikke vil blive publiceret andetsteds, herunder i nyhedsmedier, uden forudgående aftale med redaktionen,
- at alle forfattere opfylder alle fire kriterier for forfatterskab, jf. Vancouverreglerne: 1) Væsentlige bidrag til idé eller design af arbejdet, eller tilvejebringelse, analyse eller fortolkning af arbejdet. 2) Manuskriptudarbejdelse eller kritisk indholdsmæssig manuskriptrevision. 3) Godkendelse af det endelige manuskript. 4) Tilsagn om at være ansvarlig for alle aspekter i manuskriptet, idet man sikrer sig, at spørgsmål om nøjagtighed eller lødighed i enhver del af arbejdet er tilstrækkeligt undersøgt og løst.
- at bilaget "ICMJE DISCLOSURE FORM" er udfyldt og indsendt sammen med "Forfatterskabserklæring",
- at såfremt Ugeskrift for Læger publicerer det indsendte materiale, overfører vi hermed at publiceringsrettighed til Ugeskrift for Læger. Dette gælder ved publikation i enhver form og i ethvert medie,
- at artiklen publiceres under Open Access Creative Commons licens CC BY-NC-ND 4.0.

Korrespondanceansvarlig forfatter:

Navn: Thomas Baad-Hansen

Adresse: Stationsgade 9, 8240 Risskov

Telefon i dagtimerne: 28603490 E-mail: thombaad@rm.dk

Et forfatterskab forudsætter, at man opfylder alle fire kriterier for forfatterskab jf. Vancouverreglerne, nævnt ovenfor. Dette gælder også alle dem, der i multicenterstudier fremstår som forfattere. Alle andre, der har bidraget til arbejdet, og som ikke er medforfattere, skal nævnes under Taksigelser og det skal beskrives, hvad de har bidraget med. Taksigelser kan tilføjes på side 2 af dette dokument.

Manuskriptets forfattere (alle felter for hver forfatter skal udfyldes)

Navn	Institution / afdeling	Underskrift
Ahmed Abood	Tumorsektoren, Afdeling for Ortopædkirurgi, Aarhus Universitetshospital	4///
Sarah Stammose Freund,	Tumorsektoren, Afdeling for Ortopædkirurgi, Aarhus Universitetshospital	7
Michael Bendtsen	Tumorsektoren, Afdeling for Ortopædkirurgi, Aarhus Universitetshospital	Michael Milcher Done

Alle der har bidraget til arbejdet på manuskriptet, men som <u>ikke</u> opfylder alle fire kritierier for forfatterskab jf. Vancouverreglerne, skal nævnes under Taksigelser og det skal beskrives, hvad de har bidraget med.	Bjarne Hauge Hansen	Tumorsektoren, Afdeling for Ortopædkirurgi Aarhus Universitetshospital
Manuskriptets titel: Alle der har bidraget til arbejdet på manuskriptet, men som <u>ikke</u> opfylder alle fire kritierier for forfatterskab jf. Vancouverreglerne, skal nævnes under Taksigelser og det skal beskrives, hvad de har bidraget med. Det er forfatternes ansvar, at alle personer og institutioner, der nævnes under Taksigelser, har accepteret dette. Taksigelser (alle felter for hver person/institution skal udfyldes)	Thomas Baad-Hansen	Tumorsektoren, Afdeling for Ortopædkirurgi, Aarhus Universitetshospital
Alle der har bidraget til arbejdet på manuskriptet, men som <u>ikke</u> opfylder alle fire kritierier for forfatterskab jf. Vancouverreglerne, skal nævnes under Taksigelser og det skal beskrives, hvad de har bidraget med. Det er forfatternes ansvar, at alle personer og institutioner, der nævnes under Taksigelser, har accepteret dette. Taksigelser (alle felter for hver person/institution skal udfyldes)	Taksigelser:	
-	Manuskriptets titel:	
Taksigelser (alle felter for hver person/institution skal udfyldes)		
-		
Person / Institution Bidrag	Det er forfatternes ansvar, at alle p	ersoner og institutioner, der nævnes under Taksigelser, har accepteret dette.
	Taksigelser (alle felter for hv	er person/institution skal udfyldes)
	Taksigelser (alle felter for hv	er person/institution skal udfyldes)
	Taksigelser (alle felter for hv	er person/institution skal udfyldes)
	Taksigelser (alle felter for hv	er person/institution skal udfyldes)
	Taksigelser (alle felter for hv	er person/institution skal udfyldes)
	Taksigelser (alle felter for hv	er person/institution skal udfyldes)
	Taksigelser (alle felter for hv	er person/institution skal udfyldes)
	Taksigelser (alle felter for hv	er person/institution skal udfyldes)
	Taksigelser (alle felter for hv	er person/institution skal udfyldes)

Date	e : 14. oktober 2024		
You	r name: Thomas Baad-H	lansen	
Mai	nuscript title: En kva	ntitativ analyse af sammenh	ængen mellem størrelsen af caput femoris og
Mai	nuscript number (if known):	
are re third comr list a	elated to the content of yo parties whose interests ma nitment to transparency ar relationship/activity/intere	ur manuscript. "Related" ay be affected by the cont nd does not necessarily in est, it is preferable that yo	
	ollowing questions apply to uscript only.	o the author's relationship	os/activities/interests as they relate to the <u>current</u>
perta antih In ite	nins to the epidemiology of ypertensive medication, ev	hypertension, you should ven if that medication is n port for the work reporte	defined broadly. For example, if your manuscript declare all relationships with manufacturers of ot mentioned in the manuscript. d in this manuscript without time limit. For all months.
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time	e frame: Since the initial plar		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	⊠ None	
	No time limit for this item.		
			Click TAB in last row to add extra rows
Time	e frame: past 36 months		
2	Grants or contracts from	⊠ None	
	any entity (if not indicated in item #1 above).		
3	Royalties or licenses	⊠ None	

4	Consulting fees	⊠ None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	⊠ None
6	Payment for expert	N 1
О	testimony	⊠ None
	testimony	
7	Support for attending	⊠ None
	meetings and/or travel	
8	Determination and increase an	
٥	Patents planned, issued or pending	⊠ None
	pending	
9	Participation on a Data	⊠ None
	Safety Monitoring Board	
	or Advisory Board	
10	Loadorchin or fiduciary	M Name
10	Leadership or fiduciary role in other board,	⊠ None
	society, committee or	
	advocacy group, paid or	
	unpaid	
11	Stock or stock options	⊠ None
12	Receipt of equipment,	⊠ None
	materials, drugs, medical	
	writing, gifts or other	
	services	
12	Other financial and	
13	Other financial or non- financial interests	⊠ None
	imanciai interests	

🛛 I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Date	e: Klik eller tryk for at angive	e en dato.	
You	r name: Bjarne Hau	ıge Hansen	
Mar	nuscript title: En k	vantitativ analyse a	af sammenhængen mellem
Mar	nuscript number (if known): 202411	
are re third comr list a	elated to the content of yo parties whose interests ma nitment to transparency ar relationship/activity/intere	ur manuscript. "Related" ay be affected by the cont nd does not necessarily in est, it is preferable that yo	relationships/activities/interests listed below that means any relation with for-profit or not-for-profit tent of the manuscript. Disclosure represents a dicate a bias. If you are in doubt about whether to bu do so. ps/activities/interests as they relate to the current
<u>manı</u>	uscript only.		
perta antih In ite	ins to the epidemiology of ypertensive medication, ev	hypertension, you should yen if that medication is n port for the work reported	defined broadly. For example, if your manuscript declare all relationships with manufacturers of ot mentioned in the manuscript. d in this manuscript without time limit. For all months.
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time	e frame: Since the initial plan		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this	⊠ None	
	item.		
<u>. </u>			Click TAB in last row to add extra rows
Time	e frame: past 36 months		
2	Grants or contracts from any entity (if not indicated in item #1 above).	⊠ None	
3	Royalties or licenses	⊠ None	

Some	4	Consulting fees	⊠ None	
lectures, presentations, speakers bureaus, manuscript writing or educational events				
lectures, presentations, speakers bureaus, manuscript writing or educational events				
speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None	5		⊠ None	
manuscript writing or educational events 6				
educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services None				
6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None				
testimony Support for attending meetings and/or travel Support for attending for attending for a safety Monitoring Board for Advisory Board Support for attending for		educational events		
7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None	6	Payment for expert	⊠ None	
Receipt of equipment, materials, drugs, medical writing, gifts or other services None		testimony		
Receipt of equipment, materials, drugs, medical writing, gifts or other services None				
Receipt of equipment, materials, drugs, medical writing, gifts or other services None	7	Construct for attack disc	57	
8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None	/			
9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None		meetings and/or travei		
9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None				
9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None	8	Patents planned, issued or	⊠ None	
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None		pending		
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None				
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None	0	Double in chien on a Date	5	
or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None	9		⊠ None	
10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None				
role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None		or Advisory Board		
society, committee or advocacy group, paid or unpaid 11 Stock or stock options None	10		⊠ None	
advocacy group, paid or unpaid 11 Stock or stock options None Receipt of equipment, materials, drugs, medical writing, gifts or other services None None None				
11 Stock or stock options None Receipt of equipment, materials, drugs, medical writing, gifts or other services None None None				
11 Stock or stock options None Receipt of equipment, materials, drugs, medical writing, gifts or other services None None				
12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-		unpaid		
12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None	11	Stock or stock options	⊠ None	
materials, drugs, medical writing, gifts or other services 13 Other financial or non-				
materials, drugs, medical writing, gifts or other services 13 Other financial or non- None				
materials, drugs, medical writing, gifts or other services 13 Other financial or non- None			I _	
writing, gifts or other services 13 Other financial or non- None	12		⊠ None	
services 13 Other financial or non- Mone				
13 Other financial or non- 🛛 None				
<u> </u>				
financial interests	13		⊠ None	
	financ	financial interests		

🛛 I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Date	e: Klik eller tryk for at angive	e en dato.	
You	r name: Michael Be	ndtsen	
Mar	nuscript title: En k	vantitativ analyse a	af sammenhængen mellem
Mar	nuscript number (if known		<u> </u>
are re third comn	elated to the content of yo parties whose interests ma	ur manuscript. "Related" ay be affected by the cont nd does not necessarily in	relationships/activities/interests listed below that means any relation with for-profit or not-for-profit ent of the manuscript. Disclosure represents a dicate a bias. If you are in doubt about whether to ou do so.
	ollowing questions apply to uscript only.	o the author's relationship	os/activities/interests as they relate to the <u>current</u>
perta antih In ite	ins to the epidemiology of ypertensive medication, ev	hypertension, you should yen if that medication is n port for the work reported	defined broadly. For example, if your manuscript declare all relationships with manufacturers of ot mentioned in the manuscript.
otner	items, the time frame for	disclosure is the past 30 f	nontris.
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time	e frame: Since the initial plan		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	⊠ None	
	No time limit for this item.		
			Click TAB in last row to add extra rows
Time	e frame: past 36 months		CIER TAB III lust fow to dud extra fow
	e frame. past 30 months		
2	Grants or contracts from any entity (if not indicated in item #1 above).	⊠ None	
3	Royalties or licenses	⊠ None	

Some	4	Consulting fees	⊠ None	
lectures, presentations, speakers bureaus, manuscript writing or educational events				
lectures, presentations, speakers bureaus, manuscript writing or educational events				
speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None	5		⊠ None	
manuscript writing or educational events 6				
educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services None				
6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None				
testimony Support for attending meetings and/or travel Support for attending for attending for a safety Monitoring Board for Advisory Board Support for attending for		educational events		
7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None	6	Payment for expert	⊠ None	
Receipt of equipment, materials, drugs, medical writing, gifts or other services None		testimony		
Receipt of equipment, materials, drugs, medical writing, gifts or other services None				
Receipt of equipment, materials, drugs, medical writing, gifts or other services None	7	Construct for attack disc	57	
8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None	/			
9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None		meetings and/or travei		
9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None				
9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None	8	Patents planned, issued or	⊠ None	
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None		pending		
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None				
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None	0	Double in chien on a Date	5	
or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None	9		⊠ None	
10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None				
role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None		or Advisory Board		
society, committee or advocacy group, paid or unpaid 11 Stock or stock options None	10		⊠ None	
advocacy group, paid or unpaid 11 Stock or stock options None Receipt of equipment, materials, drugs, medical writing, gifts or other services None None None				
11 Stock or stock options None Receipt of equipment, materials, drugs, medical writing, gifts or other services None None None				
11 Stock or stock options None Receipt of equipment, materials, drugs, medical writing, gifts or other services None None				
12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-		unpaid		
12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None	11	Stock or stock options	⊠ None	
materials, drugs, medical writing, gifts or other services 13 Other financial or non- None				
materials, drugs, medical writing, gifts or other services 13 Other financial or non- None				
materials, drugs, medical writing, gifts or other services 13 Other financial or non- None			I _	
writing, gifts or other services 13 Other financial or non- None	12		⊠ None	
services 13 Other financial or non- Mone				
13 Other financial or non- 🛛 None				
<u> </u>				
financial interests	13		⊠ None	
	financ	financial interests		

🛛 I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Date	e: Klik eller tryk for at angive	e en dato.	
You	r name: Ahmed Abo	ood,	
Mar	nuscript title: En k	vantitativ analyse a	af sammenhængen mellem
Mar	nuscript number (if known	•	<u> </u>
are re third comn	elated to the content of yo parties whose interests ma	ur manuscript. "Related" ay be affected by the cont nd does not necessarily in	relationships/activities/interests listed below that means any relation with for-profit or not-for-profit ent of the manuscript. Disclosure represents a dicate a bias. If you are in doubt about whether to ou do so.
	ollowing questions apply to uscript only.	o the author's relationship	os/activities/interests as they relate to the <u>current</u>
perta antih In ite	ins to the epidemiology of ypertensive medication, even #1 below, report all sup	hypertension, you should yen if that medication is n port for the work reported	defined broadly. For example, if your manuscript declare all relationships with manufacturers of ot mentioned in the manuscript. d in this manuscript without time limit. For all
other	titems, the time frame for	disclosure is the past 36 r	months.
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time	e frame: Since the initial plan		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this	⊠ None	
	item.		
			Click TAB in last row to add extra rows
Time	e frame: past 36 months		
2	Grants or contracts from	⋈ None	
	any entity (if not indicated in item #1 above).		
3	Royalties or licenses	⊠ None	

Some	4	Consulting fees	⊠ None	
lectures, presentations, speakers bureaus, manuscript writing or educational events				
lectures, presentations, speakers bureaus, manuscript writing or educational events				
speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None	5		⊠ None	
manuscript writing or educational events 6				
educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services None				
6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None				
testimony Support for attending meetings and/or travel Support for attending for attending for a safety Monitoring Board for Advisory Board Support for attending for		educational events		
7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None	6	Payment for expert	⊠ None	
Receipt of equipment, materials, drugs, medical writing, gifts or other services None		testimony		
Receipt of equipment, materials, drugs, medical writing, gifts or other services None				
Receipt of equipment, materials, drugs, medical writing, gifts or other services None	7	Construct for attack disc	57	
8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None	/			
9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None		meetings and/or travei		
9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None				
9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None	8	Patents planned, issued or	⊠ None	
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None		pending		
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None				
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None	0	Double in chien on a Date	5	
or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None	9		⊠ None	
10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None				
role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None		or Advisory Board		
society, committee or advocacy group, paid or unpaid 11 Stock or stock options None	10		⊠ None	
advocacy group, paid or unpaid 11 Stock or stock options None Receipt of equipment, materials, drugs, medical writing, gifts or other services None None None				
11 Stock or stock options None Receipt of equipment, materials, drugs, medical writing, gifts or other services None None None				
11 Stock or stock options None Receipt of equipment, materials, drugs, medical writing, gifts or other services None None				
12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-		unpaid		
12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None	11	Stock or stock options	⊠ None	
materials, drugs, medical writing, gifts or other services 13 Other financial or non- None				
materials, drugs, medical writing, gifts or other services 13 Other financial or non- None				
materials, drugs, medical writing, gifts or other services 13 Other financial or non- None			I _	
writing, gifts or other services 13 Other financial or non- None	12		⊠ None	
services 13 Other financial or non- Mone				
13 Other financial or non- 🛛 None				
<u> </u>				
financial interests	13		⊠ None	
	financ	financial interests		

🛛 I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Dat	e: Klik eller tryk for at angive	e en dato.			
You	ır name: Sarah Star	mmose Freund			
Mai	nuscript title: En k	vantitativ analyse a	af sammenhængen mellem		
Mai	nuscript number (if known): 202411			
are rothind commediate to the	elated to the content of yo parties whose interests ma mitment to transparency an relationship/activity/intere	our manuscript. "Related" ay be affected by the cont nd does not necessarily in est, it is preferable that yo	relationships/activities/interests listed below that means any relation with for-profit or not-for-profit tent of the manuscript. Disclosure represents a dicate a bias. If you are in doubt about whether to bu do so. Os/activities/interests as they relate to the current		
perta antih In ite	The author's relationships/activities/interests should be <u>defined broadly</u> . For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript. In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.				
othe	·	•	·		
othe	·	•	·		
	·	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your		
	e frame: Since the initial plan	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your		
Tim	e frame: Since the initial plan All support for the present manuscript (e.g., funding,	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your		
Tim	e frame: Since the initial plan	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your		
Tim	e frame: Since the initial plane. All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges,	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your		
Tim	e frame: Since the initial plan All support for the present manuscript (e.g., funding, provision of study materials, medical writing,	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your		
Tim	e frame: Since the initial plane. All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges,	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your		
Tim	e frame: Since the initial plan All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your		
Tim	e frame: Since the initial plan All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your		
Timo	e frame: Since the initial plan All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
Tim.	e frame: Since the initial plan All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Name all entities with whom you have this relationship or indicate none (add rows as needed) nning of the work None	Specifications/Comments (e.g., if payments were made to you or to your institution)		
Timo	e frame: Since the initial plan All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. e frame: past 36 months	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
Tim.	e frame: Since the initial plan All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. e frame: past 36 months Grants or contracts from any entity (if not indicated	Name all entities with whom you have this relationship or indicate none (add rows as needed) nning of the work None	Specifications/Comments (e.g., if payments were made to you or to your institution)		
Time 2	e frame: Since the initial plan All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above).	Name all entities with whom you have this relationship or indicate none (add rows as needed) nning of the work None	Specifications/Comments (e.g., if payments were made to you or to your institution)		
Tim.	e frame: Since the initial plan All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. e frame: past 36 months Grants or contracts from any entity (if not indicated	Name all entities with whom you have this relationship or indicate none (add rows as needed) nning of the work None	Specifications/Comments (e.g., if payments were made to you or to your institution)		

Some	4	Consulting fees	⊠ None	
lectures, presentations, speakers bureaus, manuscript writing or educational events				
lectures, presentations, speakers bureaus, manuscript writing or educational events				
speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None	5		⊠ None	
manuscript writing or educational events 6				
educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services None				
6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None				
testimony Support for attending meetings and/or travel Support for attending for attending for a safety Monitoring Board for Advisory Board Support for attending for		educational events		
7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None	6	Payment for expert	⊠ None	
Receipt of equipment, materials, drugs, medical writing, gifts or other services None		testimony		
Receipt of equipment, materials, drugs, medical writing, gifts or other services None				
Receipt of equipment, materials, drugs, medical writing, gifts or other services None	7	Construct for attack disc	57	
8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None	/			
9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None		meetings and/or travei		
9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None				
9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None	8	Patents planned, issued or	⊠ None	
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None		pending		
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None				
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None	0	Double in chien on a Date	5	
or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None	9		⊠ None	
10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None				
role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None		or Advisory Board		
society, committee or advocacy group, paid or unpaid 11 Stock or stock options None	10		⊠ None	
advocacy group, paid or unpaid 11 Stock or stock options None Receipt of equipment, materials, drugs, medical writing, gifts or other services None None None				
11 Stock or stock options None Receipt of equipment, materials, drugs, medical writing, gifts or other services None None None				
11 Stock or stock options None Receipt of equipment, materials, drugs, medical writing, gifts or other services None None				
12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-		unpaid		
12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None	11	Stock or stock options	⊠ None	
materials, drugs, medical writing, gifts or other services 13 Other financial or non- None				
materials, drugs, medical writing, gifts or other services 13 Other financial or non- None				
materials, drugs, medical writing, gifts or other services 13 Other financial or non- None			I _	
writing, gifts or other services 13 Other financial or non- None	12		⊠ None	
services 13 Other financial or non- Mone				
13 Other financial or non- 🛛 None				
<u> </u>				
financial interests	13		⊠ None	
	financ	financial interests		

🛛 I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal